Thyssenkrupp's Capacity Build-Out Meets a Market Already Pricing In Better Steel

Baader raised its Thyssenkrupp price target to EUR 15.50 on steel earnings, while Goldman Sachs reported a lower voting rights share of 7.43%.

Thyssenkrupp is adding engineering and assembly muscle on two fronts, but the market's attention has drifted elsewhere. Baader Europe lifted its price target on the stock from EUR 13.90 to EUR 15.50 on Thursday, keeping a buy recommendation, after raising earnings expectations for Thyssenkrupp Steel following the division's capital markets day. That broker move, alongside a fresh stake disclosure from Goldman Sachs, now sits alongside the company's own expansion announcements — and the two strands tell rather different stories.

Two projects, two clocks

Thyssenkrupp Automotive Technology opened a development center for chassis technologies in Pune, India, on Thursday. More than 120 engineers are already working there, with the company aiming to grow the team beyond 300 over the medium term. The opening itself is complete; the headcount build-out remains a target rather than a finished fact.

Thyssenkrupp nucera, by contrast, is still at the starting line. The hydrogen unit announced its first self-operated electrolyzer cell assembly plant in Europe on October 6, with assembly scheduled to begin in 2028. One site is running today; the other exists as a plan. Treating an announcement as though it were an operating facility would misread what has actually been delivered.

What Goldman's filing does and doesn't say

Goldman Sachs reported a lower aggregate share of voting rights and financial instruments in Thyssenkrupp on Wednesday. At the threshold date of October 6, the total stood at 7.43%, down from 7.61% previously. The mandatory disclosure documents a decline, not an accumulation — and it is not the kind of event that moves a share price on its own.

The composition matters more than the headline figure. Voting rights from shares accounted for just 2.36%, while 5.07% came through instruments. The bulk of the reported total therefore sits in derivatives rather than direct equity. Investors who read stake filings as a proxy for buying or selling will draw the wrong conclusion here: a changed aggregate is not the same as a changed direct shareholding. Nor does the filing carry any new view on the business or on the value of individual divisions.

The steel story is doing the heavy lifting

Baader's upgrade rests on improved earnings expectations for the steel unit, and it is not alone in warming to the division. Jefferies flagged a recovery in the steel business roughly a week ago, with analyst Tommaso Castello also pointing to the planned spin-off of tk accelis as a factor that could narrow the conglomerate discount.

Media reports suggest the tk accelis spin-off is slated for the Frankfurt stock exchange on October 28. Thyssenkrupp has separately announced that its 2025/2026 annual report will be published on December 8, 2026. Those two dates — one a structural measure, the other the next full set of financials — frame what investors will actually be able to verify.

TK Elevator: a scenario, not a certainty

There is a further thread worth watching. Reuters reported on October 1, citing insiders, that Kone plans to sell the majority of TK Elevator's European business in order to clear antitrust objections to its planned takeover. Thyssenkrupp still indirectly holds just over 16% of TK Elevator. A successful outcome could matter for that stake — but the reported sale plans are not confirmation of a completed takeover, nor of any cash flowing back to Thyssenkrupp.

Where the burden of proof now sits

The central question is whether expanded capacity translates into business results. A working development center in Pune and an announced assembly plant are operational steps; their significance for the share depends on whether economically viable growth follows. That is a different matter from simply adding sites and staff.

The two projects cannot be judged on the same terms. In Pune, a functioning team already exists, so investors can treat the site as a completed expansion of development capacity. For nucera, the focus stays on execution through to the planned start of assembly in 2028 — a horizon that stretches well past the next earnings report. Anyone expecting a contribution to results before then would be crediting the announcement with more than it carries.

The positive path would be an expansion paired with tangible financial progress: Pune's enlarged capacity put to productive use, and nucera's build-out proceeding on schedule. Meeting a construction target would be a signal of execution; commercial validation would still have to follow. The negative path is a gap between operational spending and economic return, where additional capacity disappoints because utilization lags the plan. A larger team is not, by itself, an argument for a higher valuation.

Investors should keep three categories separate: measures already completed, targets that have been announced, and possible future earnings. The annual report on December 8 offers the next concrete checkpoint for weighing business development against expectations. For the nucera assembly plant, the execution timeline runs considerably further out. The decision, then, is not whether new sites are a good thing in principle — it is whether their expected economic impact justifies confidence before that impact has been proven.